HAVE YOU HEARD?

Established patients with an IBD specialist can request return telemedicine visits. This requires that you have a rapid internet connection, a computer with a webcam, and the ability to download software to your computer. The clerks will confirm these criteria when they check you out of clinic, and will schedule a telemedicine visit when you leave. You will receive a reminder for your visit, and will need to have your computer set up and your webcam ready to go 5 minutes before the visit time. You will be able to see your doctor, and your doctor will be able to see you, and discuss how you are doing and your ongoing care. You are still required to be seen in clinic once per year, and for urgent visits. Ask your doctor if an IBD telemedicine visit would be appropriate for your next follow up visit.

More ways to see a Michigan Medicine IBD specialist

Dr. Jami Kinnucan has opened the door to IBD patients not able to travel to Ann Arbor from the Grand Rapids area. She has opened a clinic within Metro Health for just this reason. Taking the time to travel, more patients are receiving top of the line care and the treatment needed to regain control of their health. Thank you Dr. Kinnucan!

Healthpark
2093 Health Dr, SW, Suite 302
Wyoming, MI. 49519
PH: 616-252-5775

Come take steps with us on June 9th at the Southfield Civic Center Complex.
For more information please visit ccfa.org
Currently Enrolling Clinical Trials

Ulcerative Colitis

Hickory— etrolizumab
Subcutaneous Injection
This is a phase three study for patients with moderate to severely active Ulcerative Colitis to evaluate the safety and effectiveness of etrolizumab, which targets anti-integrin b7.

ABT494— Upadacitinib
Oral tablet (Recruitment on hold until Aug. 2018)
This is a phase 2b/3 study for patients with moderate to severe Ulcerative Colitis to evaluate the safety and effectiveness of a new medication targeting JAK1.

Figaro— SHP647
Subcutaneous injection
This is a phase 3 study to evaluate the safety and efficacy of SHP647 in patients with moderate to severe Ulcerative Colitis. If eligible you will go through a 12 week induction, 52 week maintenance and a long term open label until the drug is approved by the FDA.

Legacy
Observational
This is an observational study for patients who are taking Humira for up to 10 years. This is to observe the safety of long term use of Humira for patients who have Ulcerative Colitis.

Sparc IBD - Both UC and CD
Observational
This study is meant to identify new diagnostic tests that can predict which patient will respond to which treatment and who will most likely relapse.

Entyvio PASS— Both UC and CD
Observational
This study is meant to learn more about long term use and safety of Vedolizumab, Remicade and Humira.

Crohn’s Disease

Bergamont— etrolizumab
Subcutaneous Injection
This is a phase three study for patients with moderate to severely active Crohn’s disease to evaluate the safety and effectiveness of etrolizumab, which targets anti-integrin b7.

M16-006— Risakinumab
IV Induction / Subcutaneous injections for maintenance
This is a phase 3 study to evaluate the safety and efficacy of Risakinumab in subjects with moderate to severe Crohns Disease.

Dine CD
Dietary
This study is to compare the effectiveness of a specific carbohydrate diet and Mediterranean style diet to induce symptoms and clinical remission in patients with active Crohns disease.

ABT494— Upadacitinib
Oral tablet
This is a phase 3 study to evaluate the safety and efficacy of Upadacitinib in subjects with moderate to severe Crohns Disease. If eligible, subjects could be in the study for up to 244 weeks.

Lilly—LY3074828
IV Induction / Subcutaneous injection for maintenance
This is a phase two study for patients with moderate to severe Crohn’s disease to evaluate the safety and effectiveness of a new medication targeting interleukin-23.